A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients-Reference-Cited by-同舟云学术

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients

Published:2022-08-14 Issue:5 Volume:40 Page:906-913
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Berenson James R.¹²³^ORCID,Kim Clara²,Bujarski Sean¹,To Jennifer²,Spektor Tanya M.²,Martinez Daisy²,Turner Carley²,Ghermezi Matthew²,Eades Benjamin M.¹,Swift Regina A.¹,Schwartz Gary¹,Eshaghian Shahrooz⁴,Moss Robert A.⁵,Lim Stephen⁶,Vescio Robert⁶

Affiliation:

1. Berenson Cancer Center West Hollywood Los Angeles California USA

2. Oncotherapeutics West Hollywood Los Angeles California USA

3. Institute for Myeloma and Bone Cancer Research West Hollywood Los Angeles California USA

4. Compassionate Care Research Group Fountain Valley Los Angeles California USA

5. F.A.C.P., Inc, Fountain Valley Los Angeles California USA

6. Cedars‐Sinai Medical Center Los Angeles California USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link